Sex: M
Vaccine: COVID19
Symptoms: Colitis ulcerative, Discomfort, Neck pain
Clinical narrative: Ulcerative colitis flare ups after COVID vaccine; Neck pain; Discomfort; This spontaneous case was reported by a consumer and describes the occurrence of COLITIS ULCERATIVE (Ulcerative colitis flare ups after COVID vaccine) in an adult male patient who received mRNA-1273 (Spikevax) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Ulcerative colitis.    Concurrent medical conditions included Ulcerative colitis.   On an unknown date, the patient received dose of mRNA-1273 (Spikevax) (Intramuscular) 1 dosage form and ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose. On an unknown date, the patient experienced COLITIS ULCERATIVE (Ulcerative colitis flare ups after COVID vaccine) (seriousness criterion medically significant), NECK PAIN (Neck pain) and DISCOMFORT (Discomfort). At the time of the report, COLITIS ULCERATIVE (Ulcerative colitis flare ups after COVID vaccine), NECK PAIN (Neck pain) and DISCOMFORT (Discomfort) outcome was unknown. The action taken with mRNA-1273 (Spikevax) (Intramuscular) was unknown. No concomitant medication provided. No treatment information mentioned. Patient experienced ulcerative colitis flare ups, discomfort and neck pain after COVID vaccine. This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in Company comment. This spontaneous case concerns an adult male patient with concurrent medical condition of ulcerative colitis that was treated with ADALIMUMAB (HUMIRA) who experienced the unexpected, serious (medically significant) AESI of Colitis ulcerative (Ulcerative colitis flare ups after COVID vaccine) and other non-serious events. The event occurred on an unknown date in context to a dose of mRNA-1273 vaccine. The Clinical course, Concomitant medication and treatment details were not provided, and the event outcome was unknown. The concurrent medical condition of Ulcerative colitis remains a confounder to the event's Ulcerative colitis flare up. The benefit-risk relationship of the mRNA-1273 vaccine is not affected by this report. Events seriousness was assessed as per medical judgement and available information.; Sender's Comments: This spontaneous case concerns an adult male patient with concurrent medical condition of ulcerative colitis that was treated with ADALIMUMAB (HUMIRA) who experienced the unexpected, serious (medically significant) AESI of Colitis ulcerative (Ulcerative colitis flare ups after COVID vaccine) and other non-serious events. The event occurred on an unknown date in context to a dose of mRNA-1273 vaccine. The Clinical course, Concomitant medication and treatment details were not provided, and the event outcome was unknown. The concurrent medical condition  of Ulcerative colitis remains a confounder to the event's Ulcerative colitis flare up. The benefit-risk relationship of the mRNA-1273 vaccine is not affected by this report. Events seriousness was assessed as per medical judgement and available information.